
Investors Eye Lead Plaintiff Role in GeneDx Securities Class Action
Investors who purchased GeneDx Holdings Corp. common stock between April 16, 2025, and May 4, 2026, face an August 3, 2026, deadline to move the court for lead plaintiff status. A class action lawsuit alleging securities fraud is currently underway against the company following claims of misleading business disclosures.
























